版本:
中国

BRIEF-Meeting with FDA confirms acceptability of Evoke's proposed trial for Gimoti NDA

April 4 Evoke Pharma Inc

* Positive type A meeting with FDA confirms acceptability of Evoke Pharma’S proposed comparative exposure PK trial for Gimoti NDA

* Positive type a meeting with FDA confirms acceptability of Evoke Pharma’S proposed comparative exposure PK trial for Gimoti NDA

* Company believes it will be able to submit NDA for Gimoti by late 2017 or early 2018

* After discussing protocol design of PK trial with FDA, Co plans to incorporate agency's recommendations in final protocol

* Pivotal comparative exposure PK trial will be conducted in healthy volunteers to demonstrate bioequivalence of Gimoti to Reglan tablets

* Preparing to execute PK trial and expects to have results in second half of 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐